Laddar...
A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis
BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatme...
Sparad:
| I publikationen: | J Am Soc Nephrol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Nephrology
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7062212/ https://ncbi.nlm.nih.gov/pubmed/32019783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019090944 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|